|
|
|
|
|
|
Free Newsletters
Archive
My eNewsletters
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Login
Become a Member
Discussion Forums
FAQ
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Career Definitions
Labor Market Reports
Education & Training
Regions
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
Thrombotargets Corporation Europe Inagurates New Facilities at the National Biotechnology Center in Madrid, Spain
2/1/2007
Madrid, Spain - As part of the strategic collaborations between Thrombotargets Europe S.L.(www.thrombotargets.com) and Public Research Institutions, Thrombotargets Europe has reached an agreement with the CNB, belonging to the Spanish Research Council (CSIC), to have access to a research laboratory located at the new CNB-annex building designed for the purpose of starting-up biotech initiatives.
The new 2500 square feet laboratory will be operative on the second week of February 2007 and will envisage the future growth of the company for the next three years. CNB offers to Thrombotargets Europe research team a full access to the most advanced facilities, such as proteomic and genomic services, protein design, protein tools, electron microscopy, transgenesis and animal facilities (www.cnb.uam.es). In addition, this agreement will facilitate further interaction of Thrombotargets Europe members with the research activities of one of the most advanced biotech institutes in Europe.
The potential of this new research laboratory in cooperation with tha already existing facilities in Barcelona will provide Thrombotargets the capability to undertake research projects from drug discovery to clinical trials.
|
|
|
|
|
|
|
|
|
|
|
|